Trial of BMS-986012 in Combination With Platinum and Etoposide

Official Title

A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

Summary:

The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

Trial Description

Primary Outcome:

  • Number of participants with adverse events (AEs)
  • Number of participants with serious adverse events (SAEs )
  • Discontinuations due to AEs
  • Number of participants who died due to AEs
  • Number of participants with laboratory toxicity grade shift from baseline
  • Progression Free Survival
Secondary Outcome:
  • Maximum observed serum concentration(Cmax)
  • Time of maximum observed serum concentration(Tmax)
  • Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration(AUC(0-T))
  • Observed serum concentration at the end of a dosing interval(Ctau)
  • Area under the concentration-time curve in 1 dosing interval(AUC(TAU))
  • Characterization of Immunogenicity

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society